IP Library Granted Patent US 11,203,749
Granted Patent B2
US 11,203,749 · App. 16/179,642 · Granted Dec 21, 2021

Factor VII polypeptides that are modified and uses thereof

Inventors: Edwin L. Madison (San Francisco, CA); Christopher Thanos (Tiburon, CA)
Assignee: CATALYST BIOSCIENCES, INC.
C12N9/6437C12N15/62C12Y304/21021A61K38/00A61K48/00C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,203,749
App. No.
16/179,642
Granted
Dec 21, 2021
Kind
B2
Abstract

Nucleic acids encoding modified factor VII polypeptides, vectors and cells containing the nucleic acids, uses of the nucleic acids, methods of making the encoded polypeptides, and methods of treatment are provided. The encoded modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among the encoded modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities.

Claims (6)

1. A method of catalyzing activation of a Factor X, comprising contacting the Factor X with a modified factor VII (FVII) polypeptide, wherein the modified FVII polypeptide has 1-7 amino acid replacements compared to an unmodified FVII polypeptide of SEQ ID NO: 3, wherein the modified FVII polypeptide comprises a replacement at a position corresponding to position Q286 in a FVII polypeptide having the sequence of amino acids set forth in SEQ ID NO: 3, wherein the modification at position Q286 is an amino acid replacement with Arg (R)(Q286R), wherein the modified FVII polypeptide has at least 90% sequence identity to a polypeptide of any of SEQ ID NOS.: 1-3, wherein the modified FVII polypeptide has a kinetic constant for catalytic activity greater than that of the unmodified FVII polypeptide of SEQ ID NO: 3, and wherein the modified FVII polypeptide is a single chain zymogen, a zymogen-like two-chain polypeptide, or a fully activated two-chain form.

2. The method of claim 1 , wherein the modified FVII polypeptide has only 1, 2, 3, 4, 5, 6 or 7 amino acid modifications compared to an unmodified FVII polypeptide of SEQ ID NO: 3.

3. The method of claim 1 , wherein the modified FVII polypeptide comprises a M298Q amino acid replacement.

4. The method of claim 1 , wherein the contacting is in vitro.

5. The method of claim 1 , wherein the contacting is in vivo.

6. The method of claim 1 , wherein the modified FVII polypeptide comprises amino acid replacements selected from among Q286R, Q286R/H257A, Q286R/S222A, Q286R/S222A/H257A, Q286R/S222A/Gla Swap FIX, Q286R/M298Q, Q286R/H257A/Gla Swap FIX, Q286R/S222A/H257A/Gla Swap FIX, Q286R/Q366V, Q286R/A292N/A294S/Q366V, A175S/Q286R/Q366V, S222A/Q286R/Q366V, H257S/Q286R, H257S/Q286R/Q366V, S222A/H257A/Q286R/Q366V, Q286R/H373A, S222A/H257A/Q286R/M158Q, Q286R/K341D, Q286R/Q366D, Q286R/Q366N, Q286R/H373F, T128N/P129A/Q286R/H373F, S52A/S60A/Q286R, S52A/S60A/Q286R/H373F, T239V/Q286R, T239V/Q286R/H373F, T239I/Q286R/H373F, T128N/P129A/A175S/Q286R, T128N/P129A/Q286R/M298Q, and A122N/G124S/A175S/Q286R.

Assignments (4)
SECURITY INTEREST Recorded May 26, 2026
From: USWM DEVELOPMENT CO., LLC
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 074761/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2026
From: GC BIOPHARMA CORP.
To: USWM DEVELOPMENT CO., LLC
Reel/Frame 074706/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2023
From: CATALYST BIOSCIENCES, INC.
To: GC BIOPHARMA CORP.
Reel/Frame 062943/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2018
From: MADISON, EDWIN L.; THANOS, CHRISTOPHER
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 047427/0384 →
Continuity (5)
Division 15258908 · Sep 7, 2016
Division 13987492 · Jul 30, 2013
Continuation 12384915 · Apr 10, 2009
Provisional Application 61124021 · Apr 11, 2008
Related Publication 20190055534A1 · Feb 21, 2019
Cited By (1)
US 12,385,818